Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.50 Consensus PT from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $32.29.

Several research firms recently issued reports on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Bank of America reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens reaffirmed an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd.

Catalyst Pharmaceuticals Trading Up 4.6 %

CPRX stock opened at $24.23 on Monday. Catalyst Pharmaceuticals has a 1 year low of $14.47 and a 1 year high of $24.64. The company has a fifty day simple moving average of $22.39 and a 200 day simple moving average of $21.63. The firm has a market cap of $2.94 billion, a PE ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $27,000. Park Square Financial Group LLC bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC increased its stake in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares during the period. Larson Financial Group LLC increased its stake in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at about $65,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.